Drug development

preventative and therapeutic medications for COVID-19 infection

rule of thumb that a compound is likely orally active if it violates at most one of: ≤5 hydrogen bond donors; ≤10 hydrogen bond acceptors; molecular mass of ≤500 Da; octanol-water partition coefficient of ≤5

process of bringing a new pharmaceutical drug to the market once a lead compound has been identified

type of healthcare company

according to the U.S. Food and Drug Administration, a drug that contains no active moiety that has been approved by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act

subfield of pharmacology

preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications

pharmaceutical product that successfully completed drug approval process